Global Depression Therapy & Treatment Market, by Country (United States, Canada, India, China, Japan, United Kingdom), Company Profiles, Share, Size, Trends, Analysis, Opportunities, Segmentation and Forecast 2015 - 2021

In 2013, antidepressants drugs were the third most in-demand drugs in the US and over 250 million Americans were on prescribed antidepressants. The antidepressants market in the US is among the highest in the world and is expected to grow as they are taken not only for depression but also for diseases that are not related to depression such as the non-psychological issues such as sleeplessness, eating disorders, neuropathic pain, obsessive compulsive disorder, substance abuse etc. USFDA has approved use of antidepressants for treating other conditions as well. Besides several block buster antidepressants have gone off-patents and this has led to physicians prescribe antidepressants more and more. There is no permanent cure for depression and therefore the global antidepressants market for drugs and devices continues to expand. In fact as the awareness of depression as a disease grows globally the number of patients seeking treatment is increasing exponentially thereby pushing up the demand for antidepressant devices and drugs.

W.H.O estimates that there are over 350 million people in world who suffer from depression and the depression treatment market has a huge potential to grow. The prevalence rates are very high in the Asia Pacific and African regions (4-7%). According to the W.H.O depression will soon replace heart disease as the heaviest disease burden on countries.

Depression treatment market is segmented on the basis of antidepressants drugs, devices and therapies. Antidepressants are the largest market segment. Antidepressants are the most popular treatment methods. Every year more than five billion prescriptions are written globally. Antidepressants segment consists of big pharmaceuticals companies like Eli Lily, Pfizer, GlaxoSmithKline and Forest Laboratories. All these companies are branded drug manufacturers. Some of the popular drugs produced by these companies are Cymbalta (Eli Lily) and Effexor and Pristiq (Pfizer). The devices market is the fastest growing market segment. Depression devices market is estimated to grow at a CAGR of 9% between 2015 and 2021. Devices market is driven by growing preference amongst physicians and patients due to lesser side effects. The depression treatment market witnessed an overall decline of 16% from 2013 to 2014. One of the major reasons behind this is patent expiration of major drugs and increasing use of the generic drugs. The high priced branded drugs have been replaced by generic drugs which are three times cheaper as compared to the former.

Sales of branded drugs were $7.9 billion in 2013 globally from $11 billion in 2011. Patents expired for several blockbuster branded drugs such as Prozac, Zoloft, Lexapro, and Cymbalta and generic drug manufacturers are making these drugs now. Duloxetine (Cymbalta), which had a market of $5.2 billion (2013) is expected to see the market shrunk to $3.06 billion by 2021. In the early 2000, Prozac, one of the most popular drugs had a sale of $2.5 billon, which fell to $177 million in 2002 after patent expiration. Similarly Zoloft peaked to $3.3 billion (2005) before falling to $477 million after patent expiration in 2006. Major factors expected to drive the depression drugs market, globally, are fall in the prices of antidepressants due to the entry of generic drugs, and increasing awareness of depression as a disease.

Chap 1. Executive Summary

 1.1. Depression therapy, device and drugs market
 1.2. Methodology For Market Estimation

Chap 2. Market Overview –Depression Is A Major Concern Worldwide

 2.1. Introduction
 2.2. Depression is most common in 40-60 years of age group
 2.3. Types of Depressions
 2.3.1. Seasonal Affective Disorder (SAD)
 2.3.2. Uni-polar or Major Depression
 2.3.3. Dysthymia or Dysthymia Disorder
 2.3.4. Postpartum Depression
 2.3.5. Atypical Depression
 2.3.5.1. Psychotic Depression
 2.3.5.2. Bipolar Disorder
 2.4. Value Chain Analysis
 2.4.1. For Drugs
 2.4.1.1. Manufacturers
 2.4.1.2. Distributors
 2.4.1.3. Retailers  
 2.4.1.4. End-Users  
 2.4.2. For Devices  
 2.4.2.1. Manufacturers  
 2.4.2.2. Distributors  
 2.4.2.3. End-Users  
 2.5. Drivers  
 2.5.1. Growing acceptance of Depression in the developing nations  
 2.5.2. Increase in sales of antidepressants due to unhealthy life styles  
 2.6. Restraints  
 2.6.1. High price of Psycho therapy is a major restraint  
 2.6.2. Patents expiry is a major issue  
 2.6.3. Regulatory Compliance is important for the market to grow  
 2.7. Challenges  
 2.7.1. Generic Vs Branded – leads to price reduction  
 2.8. Opportunities  
 2.8.1. Significant Unmet Clinical needs has tremendous market potential  
 2.8.2. Decline in drug market offset bygrowing demand for personal therapies & devices  
 2.9. Key Findings  
 2.9.1. Negative Growth Rate in Antidepressants market  
 2.9.2. Rising acceptance for depression treatment in Asia Pacific  
 2.9.3. Market is shifting from branded to generic drugs  
 2.10. Strategic Recommendations  
 2.10.1. Market needs new anti depressant drugs 

Chap 3. Market Segmentation  

 3.1. Antidepressants  
 3.2. Consumption of Antidepressants  
 3.2.1. Generic Drugs are preferred OVER Branded Antidepressants due to lower cost  
 3.3. Selective serotonin reuptake inhibitors (SSRIs)  
 3.3.1. Prozac (Fluoxetine)  
 3.3.2. Paroxetine (Paxil)  
 3.3.3. SERTRALINE (Zoloft)  
 3.3.4. Escitalopram oxalate (Lexapro)  
 3.3.5. Citalopram (Celexa)  
 3.3.6. Serotonin and norepinephrine reuptake inhibitors (SNRIs).  
 3.3.7. Duloxetine (Cymbalta)  
 3.3.8. Effexor  
 3.3.9. Norepinephrine and dopamine reuptake inhibitors (NDRIs)  
 3.4. Atypical antidepressants  
 3.4.1. Trazodone  
 3.4.2. Tricyclic antidepressants (TCA)  
 3.4.3. Tofranil (Imipramine)  
 3.4.4. Monoamine oxidase inhibitors (MAOIs)  
 3.4.4.1. Tranylcypromine (Parnate)  
 3.4.5. Phenelzine (Nardil)  
 3.4.6. Other medications  
 3.5. Therapies   
 3.5.1. Cognitive Behavior Therapy (CBT)  
 3.5.2. Electroconvulsive Therapy (ECT)
 3.5.3. Rational emotive behavior therapy (REBT)  
 3.5.4. Device enabled therapies  
 3.5.4.1. Transcranial Magnetic Stimulation (TMS) therapy  
 3.5.4.2. Deep Brain Stimulation  
 3.5.4.3. Vagus Nerve Stimulator  
 3.5.4.4. Virtual Reality (VR)  
 3.5.4.5. Smart phone applications
 3.5.5. Other Therapies  
 3.5.5.1. Ketamine therapy  
 3.5.6. Special Conditions  
 3.5.6.1. Antidepressants discontinuation syndrome (ADS)  
 3.5.6.2. Treatment-resistant depression  
 3.5.6.3. Rehabilitation centre for depression  
 3.5.6.4. Rehabilitation programs through VR technology 

Chap 4. Depression Prevalence by Gender 

 4.1. Depression in Men  
 4.2. Depression in Women  
 4.2.1. Depression in Elderly is a common phenomenon 

Chap 5. Resurgent Generic Drugs market due to patent expiry 

Chap 6. Competitive Trends, Strategies & Market Share 

 6.1. Key Focus on Cost Control Impacting R&D Initiatives  
 6.2. Partnerships and acquisitions  
 6.3. Generic drug manufacturers focusing on patent expiration and semi regulated markets  
 6.4. Market Share Analysis 

Chap 7. Geographical analysis 

 7.1. Devices market is growing in North America, Europe and Asia Pacific  
 7.2. North America is the highest drug market for depression  
 7.2.1. US has the largest patient pool for depression drugs & devices  
 7.2.2. US market is driven by strict regulations
 7.2.3. Mental illness is a major disease in Canada  
 7.3. Depression is a major concern in Europe  
 7.3.1. almost 16.7 million people suffer from depression in the UK  
 7.3.2. Regulations in the United Kingdom   
 7.3.3. France has the highest rate of depression amongst developed nations  
 7.3.4. Germany has prevalence rate of 4.5-5% for depression  
 7.3.5. Spain has strict regulations for depression drugs  
 7.4. Asia Pacific has a strongly emerging generic drugs market  
 7.4.1. Approx 60% of the population in China is undiagnosed for depression  
 7.4.2. India has over 10 million people suffering from depression  
 7.4.3. Financial burden of depression in Japan amounts to nearly $15 billion  
 7.4.4. Depression is a common occurring health issue in the age group 12-25 years in Australia  
 

Chap 8. Corporate profiling 

 8.1. Pfizer  
 8.1.1. Overview  
 8.1.2. Strategic Analysis  
 8.1.3. SCOT Analysis  
 8.2. GlaxoSmithKline  
 8.2.1. Overview  
 8.2.2. SCOT Analysis  
 8.3. Forest Laboratories  
 8.3.1. Overview  
 8.3.2. SCOT Analysis
 8.4. Abbot Laboratories  
 8.4.1. Overview  
 8.4.2. SCOT Analysis  
 8.5. Eli Lilly and Company  
 8.5.1. Overview  
 8.5.2. SCOT Analysis  
 8.6. Merck Sharp &Dohme  
 8.6.1. Overview  
 8.6.2. SCOT Analysis  
 8.7. Sanofi  
 8.7.1. Overview  
 8.7.2. SCOT Analysis  
 8.8. Neuronetics  
 8.8.1. Overview  
 8.8.2. SCOT Analysis  
 8.9. Teva pharmaceuticals Industries  
 8.9.1. Overview  
 8.9.2. SCOT Analysis  
 8.10. Mayo Clinic  
 8.10.1. Overview
 8.10.2. Mayo Clinic product portfolio in depression therapy  
 8.10.3. SCOT Analysis  
 8.11. Sun Pharmaceuticals  
 8.11.1. Overview  
 8.11.2. SCOT Analysis  
 8.12. Brainsway  
 8.12.1. Overview  
 8.12.2. SCOT Analysis  
 8.13. Fisher Wallace  
 8.13.1. Overview  
 8.13.2. SCOT Analysis  
 8.14. MagVentures  
 8.14.1. Overview  
 8.15. Lundbeck  
 8.15.1. Overview  
 8.15.2. Strategic moves  
 8.15.3. SCOT Analysis  
 8.16. BoehringerIngelheim GmbH  
 8.16.1. Overview  
 8.16.2. SCOT Analysis  
 8.17. Roche Holding AG  
 8.17.1. Overview  
 8.17.2. Strategic Moves  
 8.17.3. SCOT Analysis  

Table List

TABLE  1 Global Depression Drugs and Devices Market 2013- 2021 (In $million)
TABLE  2 Timeline of the branded drug expiration/Launch in the U.S.
TABLE  3 R& D spending by pharmaceutical giants in 2013
TABLE  4 Global antidepressants drug market, 2013-2021 (in $million)
TABLE  5 Price of Flouoxetine in different drug store in 2012
TABLE  6 Price of Paroxetine (Paxil), North America
TABLE  7 Global Sertaline drug market, 2013-2021, (in $million)
TABLE  8 Price and drug attribute of Lexapro
TABLE  9 Price and Package details of Cymbalta
TABLE  10 Table: U.S. Price of Effexor of different strength
TABLE  11 Price of Bupropion (Wellbutrin)
TABLE  12 Price of Trazodone of different strength
TABLE  13 Price of Tofranil of different strength
TABLE  14 Price of Tranylcypromine (Parnate)
TABLE  15 Global virtual reality in healthcare market, 2013-2021 (in $million)
TABLE  16 Difference between male and female depression behavior  
TABLE  17 Global depression drugs and device market, 2013-2021, ($million)  
TABLE  18 North America depression drugs and device market, 2013-2021, (in $million)  
TABLE  19 France has the highest prevalence rate in EU in (2014)  
TABLE  20 European depression therapy and device market, 2013-2021, ($million)  
TABLE  21 Asia Pacific depression drugs and device market, 2013-2021, (in $million)  
TABLE  22 Pfizer product portfolio in depression therapy
TABLE  23 GlaxoSmithKline product portfolio in depression therapy:  
TABLE  24 Forest Laboratories product portfolio in depression therapy  
TABLE  25 Abbot Laboratories’ product portfolio in depression therapy  
TABLE  26 Eli Lilly and Company product portfolio in depression therapy
TABLE  27 Sanofi product portfolio in depression therapy
TABLE  28 Neuronetics products portfolio in depression therapy
TABLE  29 Teva pharmaceuticals Industries product portfolio in depression therapy
TABLE  30 MagVentures product portfolio in depression therapy  
TABLE  31 Lundbeck product portfolio in depression therapy
TABLE  32 Roche AG product portfolio in depression therapy  

Figures List

FIGURE  1 DEPRESSION PREVALANCE-FACT SHEET
FIGURE  2 Worldwide Prevalence of depression by age and gender in 2013
FIGURE  3 High rate of depression in American Indian and Alaska Native –12 month prevalence of major depressive episode among U.S. adults (2012)
FIGURE  4 Lifetime prevalence RATE OF DEPRESSION IN US ADULTS, 2012
FIGURE  5 Dysthymia PATIENTS BY TREATMENT
FIGURE  6 Value Chain of Antidepressant drugs
FIGURE  7 Value Chain Analysis for Device Market
FIGURE  8 CAUSES OF DEPRESSION-(FACTORS BY PERCENTAGE, 2013)
FIGURE  9 Branded Antidepressant drug sales in $million (2003-2012)
FIGURE  10 Global Antidepressants drug market in $million (2013-2021)
FIGURE  11 Savings through generic drug usage in the United States in $billion (2004-2013)
FIGURE  12 Side effects of antidepressants
FIGURE  13 Global Flouoxetine market, 2013-2017, (in $million)
FIGURE  14 Global Escilatopram drug market, 2013-2021 (in $million)
FIGURE  15 Price of Citalopram (Celexa)
FIGURE  16 Global Duloexitine market, 2013-2021, (in $million)
FIGURE  17 Global Venlafexine drug market, 2013-2021, ($million)
FIGURE  18 Global Transcranial Magnetic Stimulation Market, 2013-2021(in $million)
FIGURE  19 Global Deep Brain Stimulation Market, 2013-2021, (in $million)
FIGURE  20 Global Vagus Nerve Stimulation Market, 2013-2021(in $million)
FIGURE  21 coMPARISON OF MALE AND FEMALE DEPRESSION
FIGURE  22 Market Share of major antidepressants in 2021 (%)
FIGURE  23 Market Share of antidepressants drug manufacturers (percentage of sales), 2014
FIGURE  24 GEOGRAPHICAL DISTRIBUTION OF prevalence rate of depression, 2013
FIGURE  25 Devices Market (percentage sales) to be the largest in 2021
FIGURE  26 The U.S. depression therapy market, 2013-2021 ($million)
FIGURE  27 Canada depression therapy market, 2013-2021, ($million)
FIGURE  28 European depression treatment device and therapy market, 2013-2021 ($million)
FIGURE  29 Devices market will double (percentage sales) in 2021 from 2013
FIGURE  30 Total cost of mental illness in England (in $)
FIGURE  31 United Kingdom depression therapy market, 2013-2021 ($million)  
FIGURE  32 France depression therapy market, 2013-2021 ($million)  
FIGURE  33 Germany depression therapy market, 2013-2021 ($million)  
FIGURE  34 Spain depression therapy market, 2013-2021 ($million)  
FIGURE  35 China depression therapy market, 2013-2021, ($million)  
FIGURE  36 India depression therapy market, 2013-2021, ($million)  
FIGURE  37 Japan depression therapy market, 2013-2021, ($million)  
FIGURE  38 Australia depression Therapy market, 2013-2021, ($million)  
FIGURE  39 Sun Pharmaceuticals products portfolio in depression therapy
FIGURE  40 Brainsway product portfolio in depression therapy
FIGURE  41 Fisher Wallace product portfolio in depression therapy 

Request for Sample